Combined chemoradiotherapy in locally advanced cancer of the uterine cervix

Trichas M1,4, Tserkezoglou A2, Barbounis V3, Hatzieleftheriou G2, Roupakia A4, Giannakouras G4, Katsilieris I4

1Department of Radiation Oncology, 401 General Army hospital, Athens, Greece

21st Department of Gynecology, Agios Savvas Oncology hospital, Athens, Greece

32nd Department of Internal Medicine, Agios Savvas Oncology hospital, Athens, Greece

43rd Department of Radiation Oncology, Agios Savvas Oncology hospital, Athens, Greece

 

Correspondence: Trichas M, 34 Dervenakion St, GR-14572 Athens, Greece. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

 


 

Abstract

The purpose of this phase II study is to investigate the response and toxicity of combined pelvic radiotherapy and cisplatin-based chemotherapy and overall survival of women with locally advanced cancer of the uterine cervix. A total of 28 eligible patients out of 33 initially enrolled in the study with stage IIB-IVA were studied and received 4 cycles of cisplatin chemotherapy (75 mg/m2 every 21 days), combined with external beam radiation therapy (EBRT) of the pelvis and intracavitary brachytherapy (maximum total dose: 85 Gy at point A). Overall response was 21/28 (15/28 CR and 6/28 PR), while 3/28 of patients had stable disease (SD) and 4/28 progressed disease (PD). Mean survival was 39.3 months and media 26 months. Toxicity was mainly mild with the exception of Grade III anemia in 25% of patients. Grade II radiation induced colitis was recorded in three patients. Preliminary results show that combination of radiotherapy and chemotherapy, as described in the protocol, is feasible and could be an effective therapeutic approach for the locally advanced cancer of uterine cervix.

Key words: chemoradiation; cisplatin; uterine cervix